Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome (Q46893987)

26 December 2017

title

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome (English)

1 reference

26 December 2017

0 references

1 reference

1 reference

1 reference

1 reference

Michiyo Deushi

1

1 reference

26 December 2017

Mitsunori Nomura

2

1 reference

26 December 2017

Akio Kawakami

3

1 reference

26 December 2017

Mihoko Haraguchi

4

1 reference

26 December 2017

Mizuho Ito

5

1 reference

26 December 2017

Mitsuyo Okazaki

6

1 reference

26 December 2017

Hideto Ishii

7

1 reference

26 December 2017

Masayuki Yoshida

8

1 reference

26 December 2017

language of work or name

English

0 references

publication date

20 November 2007

1 reference

26 December 2017

published in

FEBS Letters

1 reference

26 December 2017

volume

581

1 reference

26 December 2017

page(s)

5664-5670

1 reference

26 December 2017

issue

29

1 reference

26 December 2017

Absorption and metabolism of dietary cholesterol

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

NPC1L1: evolution from pharmacological target to physiological sterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Overproduction of large VLDL particles is driven by increased liver fat content in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

Subcutaneous vitamin E ameliorates liver injury in anin vivo model of steatocholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2007.11.023

10.1016/J.FEBSLET.2007.11.023

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

18022391

1 reference

26 December 2017